Wednesday, November 05, 2025 12:29:18 PM
Ah yes, the tired, old “bag holder” bait, used when facts fail and timelines collapse. Let’s unpack the latest attempt to reframe reality:
“LP and her financiers love such bag holders. And so do shorts.”
Translation: Retail investors who held through regulatory progress, peer-reviewed publication, and MHRA escalation are somehow the fools. Except they’re the ones who saw:
- JAMA publication of trial results
- MHRA expansion of DCVax-L’s indication
- GMP/HTA licensing of Advent’s facility
- Trial site inspections confirming regulatory engagement
If that’s what “bag holding” looks like, I’ll take two.
“Denial mindset of bag holders who don’t understand time premium…”
Time premium? You mean the same “premium” shorts paid while waiting for rejection that never came? MHRA didn’t reject. They escalated. JAMA didn’t ignore. They published. NWBO didn’t stall. They built, licensed, and deployed. (and now LP's adding unlimited scalable via Eden). You’re not describing denial, but durability, lashing out because you are rattled and recognized the end is near.
“Maybe in 2028, LP will submit reimbursement evidence in the UK…”
Cute. But let’s timestamp reality:
- MHRA has already accepted the application.
- Specials access is already operational.
- Reimbursement discussions follow approval—not precede it.
You’re mocking a future that’s already underway, trying to cope with the inevitability NWBO/DCVax-L
“Outstanding shares go over 3B in the process. ;)”
Yes, and? NWBO has no debt, no toxic financing, and no institutional overlords. Retail owns the float. The dilution funded:
- A completed Phase III trial
- A peer-reviewed publication in JAMA
- A GMP/HTA licensed facility
- A infinitely scalable mfg. process
- A regulatory submission now under review
If you’re still measuring biotech progress by share count alone, ignoring facts that undeniably points to eminent approval, your actions are tantamount to fraud. You know what's coming. You know better.
Investor082, you’ve spent years predicting collapse. NWBO keeps escalating. Every milestone you said would never happen—happened.
“LP and her financiers love such bag holders. And so do shorts.”
Translation: Retail investors who held through regulatory progress, peer-reviewed publication, and MHRA escalation are somehow the fools. Except they’re the ones who saw:
- JAMA publication of trial results
- MHRA expansion of DCVax-L’s indication
- GMP/HTA licensing of Advent’s facility
- Trial site inspections confirming regulatory engagement
If that’s what “bag holding” looks like, I’ll take two.
“Denial mindset of bag holders who don’t understand time premium…”
Time premium? You mean the same “premium” shorts paid while waiting for rejection that never came? MHRA didn’t reject. They escalated. JAMA didn’t ignore. They published. NWBO didn’t stall. They built, licensed, and deployed. (and now LP's adding unlimited scalable via Eden). You’re not describing denial, but durability, lashing out because you are rattled and recognized the end is near.
“Maybe in 2028, LP will submit reimbursement evidence in the UK…”
Cute. But let’s timestamp reality:
- MHRA has already accepted the application.
- Specials access is already operational.
- Reimbursement discussions follow approval—not precede it.
You’re mocking a future that’s already underway, trying to cope with the inevitability NWBO/DCVax-L
“Outstanding shares go over 3B in the process. ;)”
Yes, and? NWBO has no debt, no toxic financing, and no institutional overlords. Retail owns the float. The dilution funded:
- A completed Phase III trial
- A peer-reviewed publication in JAMA
- A GMP/HTA licensed facility
- A infinitely scalable mfg. process
- A regulatory submission now under review
If you’re still measuring biotech progress by share count alone, ignoring facts that undeniably points to eminent approval, your actions are tantamount to fraud. You know what's coming. You know better.
Investor082, you’ve spent years predicting collapse. NWBO keeps escalating. Every milestone you said would never happen—happened.
"Against stupidity, we are defenseless"-- Dietrich Bonhoeffer, an anti-Nazi German Theologian, executed in the final days of the Nazi regime.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
